L1 (CAM) (CD171) in ovarian serous neoplasms.
OBJECTIVE
The evaluation of L1 (CAM) as a tumor progression marker and as a prognostic factor in serous ovarian tumors.


METHODS
L1 (CAM) protein expression was assessed by immunohistochemistry and Western blot in serous ovarian tumors [cystadenomas (n = 20), borderline tumors (n = 14) and carcinomas (n = 47)], and was correlated with stage,grade, progression-free survival time (PFS) and overall survival.


RESULTS
L1 (CAM) immunoreactivity correlated significantly with stage and grade. It increased from benign tumors to early carcinomas and to advanced stage carcinomas progressively and significantly. In Stage III G3 carcinoma patients, low L1 (CAM) expressing tumors exhibited better response to chemotherapy and were associated with statistically significantly longer PFS (p = 0.002).


CONCLUSIONS
L1 (CAM) expression represents a novel diagnostic marker in serous ovarian neoplasms that shows characteristics of tumor progression. L1 expression was associated with chemotherapy response.
Daponte
A
A
Department of Obstetrics & Gynecology, University Hospital of Larissa, Larissa, Greece. dapontea@otenet.gr
Kostopoulou
E
E
Kollia
P
P
Papamichali
R
R
Vanakara
P
P
Hadjichristodoulou
C
C
Nakou
M
M
Samara
S
S
Koukoulis
G
G
Messinis
I E
IE
D014408:Biomarkers, Tumor; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D009367:Neoplasm Staging; D018297:Neoplasms, Cystic, Mucinous, and Serous / Q000378:metabolism* / Q000473:pathology; D039842:Neural Cell Adhesion Molecule L1 / Q000378:metabolism*; D010051:Ovarian Neoplasms / Q000378:metabolism* / Q000473:pathology
D014408:Biomarkers, Tumor; D039842:Neural Cell Adhesion Molecule L1